Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia

Matteo Cesari, Roger A. Fielding, Marco Pahor, Bret Goodpaster, Marc Hellerstein, Gabor A. van Kan, Stefan D. Anker, Seward Rutkove, J. Willem Vrijbloed, Maria Isaac, Yves Rolland, Christine M'Rini, Mylène Aubertin-Leheudre, Jesse M. Cedarbaum, Mauro Zamboni, Cornell C. Sieber, Didier Laurent, William J. Evans, Ronenn Roubenoff, John E. MorleyBruno Vellas, Gabor Abellan van Kan, Sandrine Andrieu, Stefan D. Anker, Patricia Anthony, Christian Asbrand, Myl̀ne Aubertin-Leheudre, Sebastien Barbart-Artigas, Olivier Benichou, Cécile Bonhomme, Pascale Borensztein, Denis Breuillé, Sergio Castro Henriquez, Jesse M. Cedarbaum, Matteo Cesari, Patricia Chatelain, Wm Cameron Chumlea, Richard V. Clark, Capucine de Meynard, William J. Evans, Gary Fanjiang, Luigi Ferrucci, Roger A. Fielding, Philippe Garnier, Sophie Gillette-Guyonnet, Bret Goodpaster, Marie Françoise Gros, Luis Miguel F Gutierrez Robledo, Marc Hellerstein, Kelly Krohn, Maria Isaac, Didier Laurent, Menghua Luo, Hélène Matheix-Fortunet, Inge Mohede, John E. Morley, Christine M'Rini, Ramon Navarro, Bruno Oesch, Reinhard Ommerborn, Marco Pahor, Patrick Ritz, Yves Rolland, Daniel Rooks, Ronnen Roubenoff, Fariba Roughead, Seward Rutkove, Cornel C. Sieber, Michèle Storrs-Malibat, Stephanie Studenski, Yannis Tsouderos, Bruno Vellas, Sjors Verlaan, Stephan von Haehling, J. Willem Vrijbloed, Sander Wijers, Mauro Zamboni

Research output: Contribution to journalArticlepeer-review

153 Scopus citations


Sarcopenia, the age-related skeletal muscle decline, is associated with relevant clinical and socioeconomic negative outcomes in older persons. The study of this phenomenon and the development of preventive/therapeutic strategies represent public health priorities. The present document reports the results of a recent meeting of the International Working Group on Sarcopenia (a task force consisting of geriatricians and scientists from academia and industry) held on June 7-8, 2011 in Toulouse (France). The meeting was specifically focused at gaining knowledge on the currently available biomarkers (functional, biological, or imaging-related) that could be utilized in clinical trials of sarcopenia and considered the most reliable and promising to evaluate age-related modifications of skeletal muscle. Specific recommendations about the assessment of aging skeletal muscle in older people and the optimal methodological design of studies on sarcopenia were also discussed and finalized. Although the study of skeletal muscle decline is still in a very preliminary phase, the potential great benefits derived from a better understanding and treatment of this condition should encourage research on sarcopenia. However, the reasonable uncertainties (derived from exploring a novel field and the exponential acceleration of scientific progress) require the adoption of a cautious and comprehensive approach to the subject.

Original languageEnglish (US)
Pages (from-to)181-190
Number of pages10
JournalJournal of Cachexia, Sarcopenia and Muscle
Issue number3
StatePublished - 2012
Externally publishedYes

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Physiology (medical)


Dive into the research topics of 'Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia'. Together they form a unique fingerprint.

Cite this